Cellectis (CLLS) Change in Account Payables (2015 - 2026)
Cellectis (CLLS) posted quarterly Change in Account Payables of -$3.9 million for Q1 2026, up 38.65% year-over-year from -$2.8 million in Q1 2025, and down 856.47% quarter-over-quarter from $510000.0 in Q3 2025.
Cellectis (CLLS) Change in Account Payables (2015 - 2026) Analysis & Trends
Cellectis' Change in Account Payables history runs 12 years deep, the most recent figure standing at -$3.9 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 38.65% year-over-year to -$3.9 million; the TTM figure through Mar 2026 stood at -$9.6 million (down 682.31% YoY), while the FY2024 annual figure was $2.1 million, up 132.59% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$3.9 million, down from $510000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $7.3 million in Q2 2022, with the low at -$6.5 million in Q1 2022.
- The 5-year median for Change in Account Payables is -$106000.0 (2024), against an average of -$663562.5.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables plunged 200.34% in 2023, then soared 524.47% in 2024.
- Cellectis' Change in Account Payables stood at $1.8 million in 2022, then slumped by 200.34% to -$1.8 million in 2023, then jumped by 268.13% to $3.0 million in 2024, then tumbled by 82.74% to $510000.0 in 2025, then tumbled by 856.47% to -$3.9 million in 2026.
- Business Quant data shows CLLS's Change in Account Payables at -$3.9 million in Q1 2026, $510000.0 in Q3 2025, and $23000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.86 Mn |
| Mar 31, 2026 | -3.86 Mn |
| Sep 30, 2025 | 510,000.00 |
| Sep 30, 2025 | 510,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Mar 31, 2025 | -6.29 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Sep 30, 2024 | -235,000.00 |
| Sep 30, 2024 | -235,000.00 |
| Jun 30, 2024 | 5.22 Mn |
| Jun 30, 2024 | 5.22 Mn |
| Mar 31, 2024 | -5.89 Mn |
| Mar 31, 2024 | -5.89 Mn |
| Dec 31, 2023 | -1.76 Mn |
| Dec 31, 2023 | -1.76 Mn |
| Sep 30, 2023 | 2.89 Mn |
| Sep 30, 2023 | 2.89 Mn |